India, June 25 -- Apollomics Inc. (APLM), a late-stage clinical biopharmaceutical company developing oncology drug candidates, announced that it has received a notice from Nasdaq indicating its non-compliance with the continued listing requirements.
Separately, the company said that, effective June 11, 2026, Apollomics formally terminated its collaboration and license Agreement with Launxp International Co., Ltd. due to Launxp's failure to remit the remaining balance of the upfront payment, along with applicable interest, and provided an update on the Vebreltinib rights.
Nasdaq Deficiency Notice The notice stated that the company no longer meets the minimum Market Value of Listed Securities (MVLS) of $35 million, required for continued li...